Janus Henderson Group PLC reduced its stake in Glaukos Corp (NYSE:GKOS) by 35.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 3,137,873 shares of the medical instruments supplier’s stock after selling 1,733,161 shares during the quarter. Janus Henderson Group PLC owned 8.99% of Glaukos worth $203,648,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of GKOS. NumerixS Investment Technologies Inc bought a new stake in Glaukos in the 2nd quarter valued at about $127,000. Great West Life Assurance Co. Can raised its stake in Glaukos by 112.0% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock valued at $172,000 after acquiring an additional 2,240 shares during the period. Valeo Financial Advisors LLC bought a new stake in Glaukos in the 2nd quarter valued at about $183,000. Prudential Financial Inc. bought a new stake in Glaukos in the 3rd quarter valued at about $203,000. Finally, Amalgamated Bank bought a new stake in Glaukos in the 2nd quarter valued at about $205,000. 98.06% of the stock is currently owned by institutional investors.
In other news, Director William J. Phd Link sold 14,475 shares of the company’s stock in a transaction dated Tuesday, November 13th. The stock was sold at an average price of $58.01, for a total transaction of $839,694.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gilbert H. Kliman sold 502,760 shares of the company’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $60.39, for a total value of $30,361,676.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 558,735 shares of company stock worth $33,592,601. Company insiders own 11.60% of the company’s stock.
Shares of GKOS opened at $57.92 on Friday. Glaukos Corp has a twelve month low of $23.08 and a twelve month high of $70.91.
Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, November 7th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.05). Glaukos had a negative net margin of 8.13% and a negative return on equity of 9.26%. The company had revenue of $43.91 million for the quarter, compared to the consensus estimate of $41.65 million. During the same quarter in the prior year, the company earned $0.04 earnings per share. The company’s quarterly revenue was up 8.7% on a year-over-year basis. As a group, equities analysts anticipate that Glaukos Corp will post -0.55 earnings per share for the current year.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Featured Story: What is an Initial Public Offering (IPO)?
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.